Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound

Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS ca...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental neurology 2013-10, Vol.248, p.16-29
Hauptverfasser: Jordão, Jessica F., Thévenot, Emmanuel, Markham-Coultes, Kelly, Scarcelli, Tiffany, Weng, Ying-Qi, Xhima, Kristiana, O'Reilly, Meaghan, Huang, Yuexi, McLaurin, JoAnne, Hynynen, Kullervo, Aubert, Isabelle
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 29
container_issue
container_start_page 16
container_title Experimental neurology
container_volume 248
creator Jordão, Jessica F.
Thévenot, Emmanuel
Markham-Coultes, Kelly
Scarcelli, Tiffany
Weng, Ying-Qi
Xhima, Kristiana
O'Reilly, Meaghan
Huang, Yuexi
McLaurin, JoAnne
Hynynen, Kullervo
Aubert, Isabelle
description Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS can deliver intravenously-administered antibodies to the brain of a mouse model of Alzheimer's disease (AD) and rapidly reduce plaques composed of amyloid-β peptides (Aβ). Here, we investigated two potential effects of transcranial FUS itself that could contribute to a reduction of plaque pathology, namely the delivery of endogenous antibodies to the brain and the activation of glial cells. We demonstrate that transcranial FUS application leads to a significant reduction in plaque burden four days after a single treatment in the TgCRND8 mouse model of AD and that endogenous antibodies are found bound to Aβ plaques. Immunohistochemical and western blot analyses showed an increase in endogenous immunoglobulins within the FUS-targeted cortex. Subsequently, microglia and astrocytes in FUS-treated cortical regions show signs of activation through increases in protein expression and changes in glial size, without changes in glial cell numbers. Enhanced activation of glia correlated with increased internalization of Aβ in microglia and astrocytes. Together these data demonstrate that FUS improved the bioavailability of endogenous antibodies and led to a temporal activation of glial cells, providing evidence towards antibody- and glia-dependent mechanisms of FUS-mediated plaque reduction. •Focused ultrasound treatment reduces amyloid-β plaque pathology within 4days.•Host immunoglobulins enter the ultrasound-treated cortex where they bind to plaques.•Microglia and astrocyte markers are increased in the ultrasound-treated cortex.•Volumes of microglia and astrocytes are increased in the ultrasound-treated cortex.•Aβ within microglia and astrocytes is increased in the ultrasound-treated cortex.
doi_str_mv 10.1016/j.expneurol.2013.05.008
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4000699</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014488613001544</els_id><sourcerecordid>1432621371</sourcerecordid><originalsourceid>FETCH-LOGICAL-c505t-284fa1dedc181d3f89e9c7a75cd06ad7ab4cc52586f7a295893e57fc2b89003f3</originalsourceid><addsrcrecordid>eNqFkc2O0zAUhS0EYsrAK4A3SCwm4dr5cbJBqkb8SSOxgbXl2DfFlWsXO6kmS16JB-GZcNVSYMXGlq6_e3x0DiEvGJQMWPt6W-L93uMcgys5sKqEpgToHpAVgx4KXlfwkKwAWF3UXddekScpbQGgr7l4TK54JUBUACvyfb1bXLCm-PmD7p36NiONaGY92eBvKHoTNujDnKjykx2CWahBZw8YlzwxdOOsclRl_KCOK3RY6BCV9cWk4gYnNDd0isonnY8jOgY9JzR0dnmcwuzNU_JoVC7hs_N9Tb68e_v59kNx9-n9x9v1XaEbaKaCd_WomEGjWcdMNXY99loo0WgDrTJCDbXWDW-6dhSK903XV9iIUfOh6wGqsbomb066-3nYZRn02YGT-2h3Ki4yKCv_ffH2q9yEg6xzbm3fZ4FXZ4EYck5pkjubNDqnPOaEJKsr3nJWCZZRcUJ1DClFHC_fMJDHAuVWXgqUxwIlNDIXmDef_-3ysve7sQy8PAMqaeXGnKu26Q8nhOhbqDO3PnGYMz1YjDJpi16jsRH1JE2w_zXzC6m9w7s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1432621371</pqid></control><display><type>article</type><title>Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Jordão, Jessica F. ; Thévenot, Emmanuel ; Markham-Coultes, Kelly ; Scarcelli, Tiffany ; Weng, Ying-Qi ; Xhima, Kristiana ; O'Reilly, Meaghan ; Huang, Yuexi ; McLaurin, JoAnne ; Hynynen, Kullervo ; Aubert, Isabelle</creator><creatorcontrib>Jordão, Jessica F. ; Thévenot, Emmanuel ; Markham-Coultes, Kelly ; Scarcelli, Tiffany ; Weng, Ying-Qi ; Xhima, Kristiana ; O'Reilly, Meaghan ; Huang, Yuexi ; McLaurin, JoAnne ; Hynynen, Kullervo ; Aubert, Isabelle</creatorcontrib><description>Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS can deliver intravenously-administered antibodies to the brain of a mouse model of Alzheimer's disease (AD) and rapidly reduce plaques composed of amyloid-β peptides (Aβ). Here, we investigated two potential effects of transcranial FUS itself that could contribute to a reduction of plaque pathology, namely the delivery of endogenous antibodies to the brain and the activation of glial cells. We demonstrate that transcranial FUS application leads to a significant reduction in plaque burden four days after a single treatment in the TgCRND8 mouse model of AD and that endogenous antibodies are found bound to Aβ plaques. Immunohistochemical and western blot analyses showed an increase in endogenous immunoglobulins within the FUS-targeted cortex. Subsequently, microglia and astrocytes in FUS-treated cortical regions show signs of activation through increases in protein expression and changes in glial size, without changes in glial cell numbers. Enhanced activation of glia correlated with increased internalization of Aβ in microglia and astrocytes. Together these data demonstrate that FUS improved the bioavailability of endogenous antibodies and led to a temporal activation of glial cells, providing evidence towards antibody- and glia-dependent mechanisms of FUS-mediated plaque reduction. •Focused ultrasound treatment reduces amyloid-β plaque pathology within 4days.•Host immunoglobulins enter the ultrasound-treated cortex where they bind to plaques.•Microglia and astrocyte markers are increased in the ultrasound-treated cortex.•Volumes of microglia and astrocytes are increased in the ultrasound-treated cortex.•Aβ within microglia and astrocytes is increased in the ultrasound-treated cortex.</description><identifier>ISSN: 0014-4886</identifier><identifier>EISSN: 1090-2430</identifier><identifier>DOI: 10.1016/j.expneurol.2013.05.008</identifier><identifier>PMID: 23707300</identifier><identifier>CODEN: EXNEAC</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Alzheimer Disease - metabolism ; Alzheimer Disease - pathology ; Alzheimer Disease - therapy ; Alzheimer's disease ; Amyloid beta-Peptides - genetics ; Amyloid beta-Peptides - metabolism ; Amyloid beta-Protein Precursor - genetics ; Amyloid beta-Protein Precursor - metabolism ; Amyloid-beta peptide ; Animals ; Astrocytes ; Autoantibodies ; Biological and medical sciences ; Blood-Brain Barrier - metabolism ; Blood-Brain Barrier - pathology ; Brain - metabolism ; Brain - pathology ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Female ; Focused ultrasound ; Immunoglobulin ; Immunoglobulin G - metabolism ; Immunoglobulin M - metabolism ; Male ; Medical sciences ; Mice ; Mice, Transgenic ; Microglia ; Neuroglia - metabolism ; Neuroglia - pathology ; Neurology ; Plaque, Amyloid - genetics ; Plaque, Amyloid - metabolism ; Plaque, Amyloid - pathology ; Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) ; Technology. Biomaterials. Equipments. Material. Instrumentation ; Transgenic mice ; Ultrasonography - methods</subject><ispartof>Experimental neurology, 2013-10, Vol.248, p.16-29</ispartof><rights>2013 Elsevier Inc.</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><rights>2013 Elsevier Inc. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c505t-284fa1dedc181d3f89e9c7a75cd06ad7ab4cc52586f7a295893e57fc2b89003f3</citedby><cites>FETCH-LOGICAL-c505t-284fa1dedc181d3f89e9c7a75cd06ad7ab4cc52586f7a295893e57fc2b89003f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.expneurol.2013.05.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3548,27922,27923,45993</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27779604$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23707300$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jordão, Jessica F.</creatorcontrib><creatorcontrib>Thévenot, Emmanuel</creatorcontrib><creatorcontrib>Markham-Coultes, Kelly</creatorcontrib><creatorcontrib>Scarcelli, Tiffany</creatorcontrib><creatorcontrib>Weng, Ying-Qi</creatorcontrib><creatorcontrib>Xhima, Kristiana</creatorcontrib><creatorcontrib>O'Reilly, Meaghan</creatorcontrib><creatorcontrib>Huang, Yuexi</creatorcontrib><creatorcontrib>McLaurin, JoAnne</creatorcontrib><creatorcontrib>Hynynen, Kullervo</creatorcontrib><creatorcontrib>Aubert, Isabelle</creatorcontrib><title>Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound</title><title>Experimental neurology</title><addtitle>Exp Neurol</addtitle><description>Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS can deliver intravenously-administered antibodies to the brain of a mouse model of Alzheimer's disease (AD) and rapidly reduce plaques composed of amyloid-β peptides (Aβ). Here, we investigated two potential effects of transcranial FUS itself that could contribute to a reduction of plaque pathology, namely the delivery of endogenous antibodies to the brain and the activation of glial cells. We demonstrate that transcranial FUS application leads to a significant reduction in plaque burden four days after a single treatment in the TgCRND8 mouse model of AD and that endogenous antibodies are found bound to Aβ plaques. Immunohistochemical and western blot analyses showed an increase in endogenous immunoglobulins within the FUS-targeted cortex. Subsequently, microglia and astrocytes in FUS-treated cortical regions show signs of activation through increases in protein expression and changes in glial size, without changes in glial cell numbers. Enhanced activation of glia correlated with increased internalization of Aβ in microglia and astrocytes. Together these data demonstrate that FUS improved the bioavailability of endogenous antibodies and led to a temporal activation of glial cells, providing evidence towards antibody- and glia-dependent mechanisms of FUS-mediated plaque reduction. •Focused ultrasound treatment reduces amyloid-β plaque pathology within 4days.•Host immunoglobulins enter the ultrasound-treated cortex where they bind to plaques.•Microglia and astrocyte markers are increased in the ultrasound-treated cortex.•Volumes of microglia and astrocytes are increased in the ultrasound-treated cortex.•Aβ within microglia and astrocytes is increased in the ultrasound-treated cortex.</description><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer Disease - therapy</subject><subject>Alzheimer's disease</subject><subject>Amyloid beta-Peptides - genetics</subject><subject>Amyloid beta-Peptides - metabolism</subject><subject>Amyloid beta-Protein Precursor - genetics</subject><subject>Amyloid beta-Protein Precursor - metabolism</subject><subject>Amyloid-beta peptide</subject><subject>Animals</subject><subject>Astrocytes</subject><subject>Autoantibodies</subject><subject>Biological and medical sciences</subject><subject>Blood-Brain Barrier - metabolism</subject><subject>Blood-Brain Barrier - pathology</subject><subject>Brain - metabolism</subject><subject>Brain - pathology</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Female</subject><subject>Focused ultrasound</subject><subject>Immunoglobulin</subject><subject>Immunoglobulin G - metabolism</subject><subject>Immunoglobulin M - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Microglia</subject><subject>Neuroglia - metabolism</subject><subject>Neuroglia - pathology</subject><subject>Neurology</subject><subject>Plaque, Amyloid - genetics</subject><subject>Plaque, Amyloid - metabolism</subject><subject>Plaque, Amyloid - pathology</subject><subject>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</subject><subject>Technology. Biomaterials. Equipments. Material. Instrumentation</subject><subject>Transgenic mice</subject><subject>Ultrasonography - methods</subject><issn>0014-4886</issn><issn>1090-2430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2O0zAUhS0EYsrAK4A3SCwm4dr5cbJBqkb8SSOxgbXl2DfFlWsXO6kmS16JB-GZcNVSYMXGlq6_e3x0DiEvGJQMWPt6W-L93uMcgys5sKqEpgToHpAVgx4KXlfwkKwAWF3UXddekScpbQGgr7l4TK54JUBUACvyfb1bXLCm-PmD7p36NiONaGY92eBvKHoTNujDnKjykx2CWahBZw8YlzwxdOOsclRl_KCOK3RY6BCV9cWk4gYnNDd0isonnY8jOgY9JzR0dnmcwuzNU_JoVC7hs_N9Tb68e_v59kNx9-n9x9v1XaEbaKaCd_WomEGjWcdMNXY99loo0WgDrTJCDbXWDW-6dhSK903XV9iIUfOh6wGqsbomb066-3nYZRn02YGT-2h3Ki4yKCv_ffH2q9yEg6xzbm3fZ4FXZ4EYck5pkjubNDqnPOaEJKsr3nJWCZZRcUJ1DClFHC_fMJDHAuVWXgqUxwIlNDIXmDef_-3ysve7sQy8PAMqaeXGnKu26Q8nhOhbqDO3PnGYMz1YjDJpi16jsRH1JE2w_zXzC6m9w7s</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Jordão, Jessica F.</creator><creator>Thévenot, Emmanuel</creator><creator>Markham-Coultes, Kelly</creator><creator>Scarcelli, Tiffany</creator><creator>Weng, Ying-Qi</creator><creator>Xhima, Kristiana</creator><creator>O'Reilly, Meaghan</creator><creator>Huang, Yuexi</creator><creator>McLaurin, JoAnne</creator><creator>Hynynen, Kullervo</creator><creator>Aubert, Isabelle</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20131001</creationdate><title>Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound</title><author>Jordão, Jessica F. ; Thévenot, Emmanuel ; Markham-Coultes, Kelly ; Scarcelli, Tiffany ; Weng, Ying-Qi ; Xhima, Kristiana ; O'Reilly, Meaghan ; Huang, Yuexi ; McLaurin, JoAnne ; Hynynen, Kullervo ; Aubert, Isabelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c505t-284fa1dedc181d3f89e9c7a75cd06ad7ab4cc52586f7a295893e57fc2b89003f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer Disease - therapy</topic><topic>Alzheimer's disease</topic><topic>Amyloid beta-Peptides - genetics</topic><topic>Amyloid beta-Peptides - metabolism</topic><topic>Amyloid beta-Protein Precursor - genetics</topic><topic>Amyloid beta-Protein Precursor - metabolism</topic><topic>Amyloid-beta peptide</topic><topic>Animals</topic><topic>Astrocytes</topic><topic>Autoantibodies</topic><topic>Biological and medical sciences</topic><topic>Blood-Brain Barrier - metabolism</topic><topic>Blood-Brain Barrier - pathology</topic><topic>Brain - metabolism</topic><topic>Brain - pathology</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Female</topic><topic>Focused ultrasound</topic><topic>Immunoglobulin</topic><topic>Immunoglobulin G - metabolism</topic><topic>Immunoglobulin M - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Microglia</topic><topic>Neuroglia - metabolism</topic><topic>Neuroglia - pathology</topic><topic>Neurology</topic><topic>Plaque, Amyloid - genetics</topic><topic>Plaque, Amyloid - metabolism</topic><topic>Plaque, Amyloid - pathology</topic><topic>Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)</topic><topic>Technology. Biomaterials. Equipments. Material. Instrumentation</topic><topic>Transgenic mice</topic><topic>Ultrasonography - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jordão, Jessica F.</creatorcontrib><creatorcontrib>Thévenot, Emmanuel</creatorcontrib><creatorcontrib>Markham-Coultes, Kelly</creatorcontrib><creatorcontrib>Scarcelli, Tiffany</creatorcontrib><creatorcontrib>Weng, Ying-Qi</creatorcontrib><creatorcontrib>Xhima, Kristiana</creatorcontrib><creatorcontrib>O'Reilly, Meaghan</creatorcontrib><creatorcontrib>Huang, Yuexi</creatorcontrib><creatorcontrib>McLaurin, JoAnne</creatorcontrib><creatorcontrib>Hynynen, Kullervo</creatorcontrib><creatorcontrib>Aubert, Isabelle</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jordão, Jessica F.</au><au>Thévenot, Emmanuel</au><au>Markham-Coultes, Kelly</au><au>Scarcelli, Tiffany</au><au>Weng, Ying-Qi</au><au>Xhima, Kristiana</au><au>O'Reilly, Meaghan</au><au>Huang, Yuexi</au><au>McLaurin, JoAnne</au><au>Hynynen, Kullervo</au><au>Aubert, Isabelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound</atitle><jtitle>Experimental neurology</jtitle><addtitle>Exp Neurol</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>248</volume><spage>16</spage><epage>29</epage><pages>16-29</pages><issn>0014-4886</issn><eissn>1090-2430</eissn><coden>EXNEAC</coden><abstract>Noninvasive, targeted drug delivery to the brain can be achieved using transcranial focused ultrasound (FUS), which transiently increases the permeability of the blood–brain barrier (BBB) for localized delivery of therapeutics from the blood to the brain. Previously, we have demonstrated that FUS can deliver intravenously-administered antibodies to the brain of a mouse model of Alzheimer's disease (AD) and rapidly reduce plaques composed of amyloid-β peptides (Aβ). Here, we investigated two potential effects of transcranial FUS itself that could contribute to a reduction of plaque pathology, namely the delivery of endogenous antibodies to the brain and the activation of glial cells. We demonstrate that transcranial FUS application leads to a significant reduction in plaque burden four days after a single treatment in the TgCRND8 mouse model of AD and that endogenous antibodies are found bound to Aβ plaques. Immunohistochemical and western blot analyses showed an increase in endogenous immunoglobulins within the FUS-targeted cortex. Subsequently, microglia and astrocytes in FUS-treated cortical regions show signs of activation through increases in protein expression and changes in glial size, without changes in glial cell numbers. Enhanced activation of glia correlated with increased internalization of Aβ in microglia and astrocytes. Together these data demonstrate that FUS improved the bioavailability of endogenous antibodies and led to a temporal activation of glial cells, providing evidence towards antibody- and glia-dependent mechanisms of FUS-mediated plaque reduction. •Focused ultrasound treatment reduces amyloid-β plaque pathology within 4days.•Host immunoglobulins enter the ultrasound-treated cortex where they bind to plaques.•Microglia and astrocyte markers are increased in the ultrasound-treated cortex.•Volumes of microglia and astrocytes are increased in the ultrasound-treated cortex.•Aβ within microglia and astrocytes is increased in the ultrasound-treated cortex.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>23707300</pmid><doi>10.1016/j.expneurol.2013.05.008</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0014-4886
ispartof Experimental neurology, 2013-10, Vol.248, p.16-29
issn 0014-4886
1090-2430
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4000699
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Alzheimer Disease - metabolism
Alzheimer Disease - pathology
Alzheimer Disease - therapy
Alzheimer's disease
Amyloid beta-Peptides - genetics
Amyloid beta-Peptides - metabolism
Amyloid beta-Protein Precursor - genetics
Amyloid beta-Protein Precursor - metabolism
Amyloid-beta peptide
Animals
Astrocytes
Autoantibodies
Biological and medical sciences
Blood-Brain Barrier - metabolism
Blood-Brain Barrier - pathology
Brain - metabolism
Brain - pathology
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Female
Focused ultrasound
Immunoglobulin
Immunoglobulin G - metabolism
Immunoglobulin M - metabolism
Male
Medical sciences
Mice
Mice, Transgenic
Microglia
Neuroglia - metabolism
Neuroglia - pathology
Neurology
Plaque, Amyloid - genetics
Plaque, Amyloid - metabolism
Plaque, Amyloid - pathology
Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects)
Technology. Biomaterials. Equipments. Material. Instrumentation
Transgenic mice
Ultrasonography - methods
title Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T19%3A37%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Amyloid-%CE%B2%20plaque%20reduction,%20endogenous%20antibody%20delivery%20and%20glial%20activation%20by%20brain-targeted,%20transcranial%20focused%20ultrasound&rft.jtitle=Experimental%20neurology&rft.au=Jord%C3%A3o,%20Jessica%20F.&rft.date=2013-10-01&rft.volume=248&rft.spage=16&rft.epage=29&rft.pages=16-29&rft.issn=0014-4886&rft.eissn=1090-2430&rft.coden=EXNEAC&rft_id=info:doi/10.1016/j.expneurol.2013.05.008&rft_dat=%3Cproquest_pubme%3E1432621371%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1432621371&rft_id=info:pmid/23707300&rft_els_id=S0014488613001544&rfr_iscdi=true